Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification

被引:2
|
作者
Feng, Lijuan [1 ]
Kan, Ying [1 ]
Wang, Wei [1 ]
Wang, Chao [2 ]
Zhang, Hui [3 ]
Xie, Peng [4 ]
Yang, Jigang [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Nucl Med, 95 Yong Rd, Beijing 100050, Peoples R China
[2] SinoUn Healthcare Inc, Beijing 100192, Peoples R China
[3] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China
[4] Hebei Med Univ, Hosp 3, Dept Nucl Med, Shijiazhuang 050051, Peoples R China
关键词
Event-free survival; Neuroblastoma; Nomogram; Overall survival; Prognosis; MITOSIS-KARYORRHEXIS INDEX; CLASSIFICATION;
D O I
10.1007/s00432-023-05398-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTo develop and validate a nomogram for predicting survival in intermediate- and high-risk neuroblastoma patients and to compare the accuracy of the nomogram in predicting survival with Children's Oncology Group (COG) risk stratification.MethodsA total of 885 intermediate- and high-risk neuroblastoma patients were enrolled in this study, including 243 patients from our hospital (the training set) and 642 patients from the TARGET database (the validation set). The factors related to event-free survival (EFS) and overall survival (OS) in neuroblastoma were determined to construct the nomogram by Cox regression analysis. The C-index, calibration curves, and area under the time-dependent receiver operating characteristic curves (AUCs) were used to assess the predictive performance of the nomogram.ResultsInternational Neuroblastoma Staging System stage and Mitosis-karyorrhexis index (MKI) were significant unfavorable factors for EFS, while MKI and MYCN status were significant unfavorable factors for OS. The C-index of the nomogram was 0.621 and 0.586 for predicting EFS, 0.650 and 0.570 for predicting OS in the training and validation sets, respectively. The calibration curves revealed good agreement in the EFS and OS predicted by the nomogram. The AUCs of the nomogram for 1-, 2-, 3-year EFS and OS were 0.633, 0.669, 0.604 and 0.672, 0.670, 0.702 in the training set, respectively. Moreover, the nomogram was able to classify patients into two groups according to risk scores, with the "high-risk" group having a lower survival rate than the "intermediate-risk" group. And the nomogram performed better than the COG risk stratification, which had a C-index of 0.537, 0.502 and 0.565, 0.572 for predicting EFS, OS in the training and validation sets, respectively.ConclusionWe developed and validated a prognostic nomogram for intermediate- and high-risk neuroblastoma patients that clinicians can use to make more informed decisions for individual patients.
引用
收藏
页码:16377 / 16390
页数:14
相关论文
共 50 条
  • [31] Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children's Oncology Group clinical trials.
    Umaretiya, Puja J.
    Naranjo, Arlene
    Zhang, Fan
    Park, Julie R.
    Weiss, Brian D.
    Granger, Meaghan
    DuBois, Steven G.
    Bagatell, Rochelle
    Bona, Kira
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Impact of radiotherapy for high-risk neuroblastoma: A children's cancer group study
    Haas-Kogan, DA
    Swift, PS
    Selch, M
    Haase, GM
    Seeger, RC
    Gerbing, RB
    Stram, DO
    Matthay, KK
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01): : 28 - 39
  • [33] Outcomes of the POG 9340/9341/9342 Trials for Children With High-Risk Neuroblastoma: A Report From the Children's Oncology Group
    Zage, Peter E.
    Kletzel, Morris
    Murray, Kevin
    Marcus, Robert
    Castleberry, Robert
    Zhang, Yang
    London, Wendy B.
    Kretschmar, Cynthia
    PEDIATRIC BLOOD & CANCER, 2008, 51 (06) : 747 - 753
  • [34] Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales-A report from the Children's Oncology Group (COG).
    Landier, W.
    Knight, K. R.
    Wong, F. L.
    Lee, J. K.
    Thomas, O.
    Kim, H.
    Kreissman, S. G.
    Schmidt, M. L.
    Chen, L.
    London, W. B.
    Bhatia, S.
    Gurney, J. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Development and validation of nomogram for predicting the risk of transferring to the ICU for children with influenza
    Sun, Ruiyang
    Zhang, Xue
    Hou, Jiapu
    Jia, Wanyu
    Li, Peng
    Song, Chunlan
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (09) : 1795 - 1805
  • [36] Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group
    London, WB
    Castleberry, RP
    Matthay, KK
    Look, AT
    Seeger, RC
    Shimada, H
    Thorner, P
    Brodeur, G
    Maris, JM
    Reynolds, CP
    Cohn, SL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6459 - 6465
  • [37] Development and validation of a novel nomogram for predicting overall survival patients with neuroblastoma
    Zhao, Jin-du
    Lu, Xian-ying
    Chen, Tian -ping
    Duan, Xian-Lun
    Zuo, Wei
    Sai, Kai
    Zhu, Li -ran
    Gao, Qun
    EJSO, 2024, 50 (06):
  • [38] Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)
    Pinto, Navin
    Naranjo, Arlene
    Hibbitts, Emily
    Kreissman, Susan G.
    Granger, M. Meaghan
    Irwin, Meredith S.
    Bagatell, Rochelle
    London, Wendy B.
    Greengard, Emily G.
    Park, Julie R.
    Dubois, Steven G.
    EUROPEAN JOURNAL OF CANCER, 2019, 112 : 66 - 79
  • [39] Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
    Pinto, Navin R.
    Hibbitts, Emily
    Kreissman, Susan G.
    Granger, Meaghan P.
    Irwin, Meredith
    Bagatell, Rochelle
    London, Wendy B.
    Greengard, Emily Gustava
    Naranjo, Arlene
    Park, Julie R.
    DuBois, Steven G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Rituximab is Highly Effective in Children and Adolescents with Intermediate- and High-Risk Burkitt Lymphoma
    Zhen, Z.
    Zhu, J.
    Wang, J.
    Lu, S.
    Sun, F.
    Huang, J.
    Sun, X.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S84 - S84